What Are Compounded Semaglutides and How Do They Differ from FDA-Approved Options?

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

A compounded semaglutide preparation is made by a state-licensed pharmacy against a prescription written for one named patient. An FDA-approved semaglutide product — Ozempic, Wegovy, Rybelsus or Ozempic tablets — is a finished product whose application the FDA reviewed and approved before it could be sold. That single structural difference produces every other difference between the two categories: labeling, evidence, oversight, and what can lawfully be claimed. The FDA states directly that compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before marketing.

Approval Is a Review, Not a Certification of the Molecule

An FDA approval attaches to an application supported by specific evidence for a specific population and purpose. Wegovy holds weight-management, cardiovascular and MASH indications. Ozempic holds three type 2 diabetes indications. Rybelsus and Ozempic tablets share a label covering glycemic control and cardiovascular risk reduction.

Each of those approvals carries reviewed labeling: a boxed warning about thyroid C-cell tumors observed in rodents, contraindications, warnings and precautions, an adverse reaction table drawn from the trials, drug interaction findings, and clinical studies sections.

A compounded preparation has none of that in its own right. There is no FDA-reviewed prescribing information for a compounded semaglutide preparation, no agency-reviewed adverse reaction table, and no approved indication.

Compounded Is Not Generic, and Not "the Same Drug"

The FDA is explicit that compounded drugs are not the same as generic drugs. A generic must establish therapeutic equivalence to a reference listed drug through an abbreviated new drug application. No approved generic semaglutide exists.

The agency also lists, among its telehealth red flags, any company that makes claims such as the compounded drug being the same as an FDA-approved drug. That is not a stylistic preference; it is a marketing claim the agency treats as a warning sign.

Salt forms sharpen the point. The FDA states that semaglutide sodium and semaglutide acetate are different active ingredients from the one used in the approved drugs, that it lacks information on whether they share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding.

The Legitimate Role of Compounding

None of this makes compounding illegitimate. It is a long-established part of pharmacy practice with a statutory basis. Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional pharmacy compounding against a valid prescription for an identified individual patient, primarily under state board of pharmacy regulation.

The FDA’s own position is that a compounded drug might be appropriate when a patient’s medical need cannot be met by an FDA-approved drug, or when the approved drug is not commercially available. That is a real clinical space, not a loophole.

PlexusDx works only with licensed 503A compounding pharmacies. The distinction from section 503B outsourcing facilities matters because the two operate under different regulatory obligations.

Where the Evidence Differs

The efficacy figures everyone quotes come from the approved products. STEP 1 reported a mean weight change of −14.9% versus −2.4% with placebo over 68 weeks in 1,961 adults. Study 8 in the Wegovy label reported −18.8% at 7.2 mg and −15.5% at 2.4 mg versus −3.9% over 72 weeks in 1,407 participants.

Those trials studied the approved formulations, at labeled dosages, with defined manufacturing controls. They are not evidence about any particular compounded preparation, which may differ in concentration, excipients, container and beyond-use dating.

This is why quoting trial results as though they describe a compounded preparation overstates what is known. The molecule may be the same; the product studied was not.

The Documented Risk Signals

As of May 31, 2026 the FDA reported receiving 990 adverse event reports associated with compounded semaglutide and more than 730 for compounded tirzepatide, while noting that state-licensed pharmacies which are not outsourcing facilities are not federally required to submit such reports, so the counts are likely low.

A recurring category is dosing error: patients measuring and self-administering incorrect doses, clinicians miscalculating doses, and prescribing beyond what appears in the approved label. Some events required hospitalization.

The agency has also documented fraudulent compounded products whose labels name pharmacies that did not compound them or that do not exist, and has established an import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns.

How to Compare Them Honestly

On regulatory status: approved products have been reviewed; compounded preparations have not. On labeling: approved products have FDA-reviewed prescribing information; compounded preparations do not. On evidence: the trial data belong to the approved formulations.

On access: compounded preparations are typically cash-pay, are not covered by formularies, and are dispensed after an individual prescription. On oversight: state boards of pharmacy are the primary regulator for 503A compounding, with FDA involvement in specific conditions.

Anyone presenting compounded semaglutide as identical to an approved brand is misdescribing it. Anyone presenting it as inherently illegitimate is also wrong. The accurate description is a different regulatory category with a genuine clinical role and a documented set of risks.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What exactly is compounded semaglutide?

It is a preparation made by a state-licensed pharmacy against a prescription written for one identified patient, under section 503A of the Federal Food, Drug, and Cosmetic Act. It is not an FDA-approved finished product, has no FDA-reviewed prescribing information of its own, and the agency does not review it for safety, effectiveness or quality before it is marketed.

Is compounded semaglutide a generic version of Ozempic or Wegovy?

No. The FDA explicitly distinguishes compounded drugs from generic drugs, which must establish therapeutic equivalence to a reference listed drug through an abbreviated application. No approved generic semaglutide exists. The agency also lists claims that a compounded drug is the same as an FDA-approved drug among its telehealth warning signs for consumers.

Do the clinical trial results apply to compounded preparations?

Not directly. STEP 1 and the Wegovy label studies tested the approved formulations at labeled dosages with defined manufacturing controls. A compounded preparation may differ in concentration, excipients, container and beyond-use dating. Quoting those results as though they describe a specific compounded preparation overstates what has actually been demonstrated about that preparation.

When is compounding actually appropriate?

The FDA states that a compounded drug might be appropriate when a patient’s medical need cannot be met by an FDA-approved drug, or when the approved drug is not commercially available. Compounding is a long-established statutory part of pharmacy practice. The agency also directs that patients obtain a prescription from their doctor and fill it at a state-licensed pharmacy.

What are semaglutide salt forms and why do they matter?

Semaglutide sodium and semaglutide acetate are salt forms that the FDA describes as different active ingredients from the one used in the approved drugs. The agency says it does not have information on whether these salts share the same chemical and pharmacologic properties as the approved active ingredient, and that it is not aware of any lawful basis for their use in compounding.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.